April 17, 2015
Pharmacosmos introduces DEAE-Dextran
Pharmacosmos has introduced DEAE-Dextran as part of the company's extensive array of biopolymers for pharmaceutical use. The company sees the introduction as part of a dedicated continuing effort to developing and supplying its customers with high quality dextran derivatives.
"Our DEAE-Dextran is graced with the same high quality as our other dextran derivatives, and we believe that we by introducing DEAE-Dextran as part of our already extensive portfolio are able to build an even stronger position in the market," said Dr Lars Christensen, CEO at Pharmacosmos.
Pharmacosmos is a world leader in pharmaceutical dextran solutions and counts tailor-made solutions to special carbohydrate needs among its forces. The company is the only dextran provider approved by the US FDA and EDQM in Europe, and Pharmacosmos operates on the basis of an innovative and unique manufacturing process without the use of organic solvents.
Dextran is used in a number of areas, among other ophthalmic, vaccines, cryopreservation, lyophilization and volume expansion.
For more information, please see:
https://www.dextran.com/application-areas
https://www.dextran.com/products/dextran-derivatives/deae-dextran-500
Additional information:
Anne Marie Oerkild
International Sales and Business Director
M: +45 2788 8766
E: amo@pharmacosmos.com
W: www.dextran.com
Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.
Pharmacosmos has subsidiaries in US, China, UK, Ireland, Germany, Sweden and Norway and its products are marketed in more than 80 countries around the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.
Dextran is used in a number of areas, among other ophthalmic, oral application/tablets, vaccines, cryopreservation, lyophilization and volume expansion.
DEAE-Dextran (Diethylaminoethyl-Dextran) is a polycatonic derivative of Dextran. DEAE-Dextran is used for a number of applications hereunder as vaccine adjuvant, in gene therapy, and protein stabilization.
